<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114006</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00001470</org_study_id>
    <nct_id>NCT04114006</nct_id>
  </id_info>
  <brief_title>Novel Screening Modality for Early Gastric Cancer</brief_title>
  <official_title>Initial Analysis of Wide-area Transepithelial Sampling (WATS) With 3-dimensional Computer Assisted Analysis for the Detection of Gastric Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Potential patients will be recruited at participating sites based on routine care with
      clinical indications for upper endoscopy. After careful review of their inclusion and
      exclusion criteria, patients will be approached regarding the study and if interested, they
      will be consented and usual standard of care procedures performed. Patients will undergo
      their scheduled endoscopy with standard forceps biopsies along with WATS brush samples.
      Documentation of the consent process and procedure will be done as well as data collection
      related to this study. All samples including standard of care samples and WATS samples will
      be sent for histologic analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic yield of the WATS approach versus standard gastric biopsy mapping</measure>
    <time_frame>1-2 Years</time_frame>
    <description>To compare the diagnostic yield of the WATS approach versus standard gastric biopsy mapping (per the updated Sydney system).</description>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastric Cancer</condition>
  <biospec_descr>
    <textblock>
      Tissue biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with indications for upper endoscopy (e.g. dyspepsia)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is informed of the investigational nature of this study and given verbal and
             written informed consent in accordance with local, U.S., and international guidelines.

          -  Both males and females at least 18 years.

          -  Patients with clinical indications for upper endoscopy

        Exclusion Criteria:

          -  Patients should not have an advanced medical or psychiatric conditions which that may
             limit their ability to participate in the study, as judged by the physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Morgan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Dominguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Occidente Honduras</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatiana Torres Herman, MD, MHS</last_name>
    <phone>205-934-1015</phone>
    <email>ttherman@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Occidente</name>
      <address>
        <city>Santa Rosa De Cop√°n</city>
        <state>Copan</state>
        <zip>41101</zip>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Dominguez, MD</last_name>
      <phone>504-9566-0258</phone>
      <email>ricardod@camo.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Honduras</country>
  </location_countries>
  <reference>
    <citation>Vennalaganti PR, Kaul V, Wang KK, Falk GW, Shaheen NJ, Infantolino A, Johnson DA, Eisen G, Gerson LB, Smith MS, Iyer PG, Lightdale CJ, Schnoll-Sussman F, Gupta N, Gross SA, Abrams J, Haber GB, Chuttani R, Pleskow DK, Kothari S, Goldblum JR, Zhang Y, Sharma P. Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. Gastrointest Endosc. 2018 Feb;87(2):348-355. doi: 10.1016/j.gie.2017.07.039. Epub 2017 Jul 27.</citation>
    <PMID>28757316</PMID>
  </reference>
  <reference>
    <citation>ASGE STANDARDS OF PRACTICE COMMITTEE, Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S, Agrawal D, Buxbaum JL, Fishman DS, Gurudu SR, Jue TL, Kripalani S, Lee JK, Khashab MA, Naveed M, Thosani NC, Yang J, DeWitt J, Wani S; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. doi: 10.1016/j.gie.2019.05.012.</citation>
    <PMID>31439127</PMID>
  </reference>
  <reference>
    <citation>Banks M, Graham D, Jansen M, Gotoda T, Coda S, di Pietro M, Uedo N, Bhandari P, Pritchard DM, Kuipers EJ, Rodriguez-Justo M, Novelli MR, Ragunath K, Shepherd N, Dinis-Ribeiro M. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019 Sep;68(9):1545-1575. doi: 10.1136/gutjnl-2018-318126. Epub 2019 Jul 5.</citation>
    <PMID>31278206</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Douglas Morgan MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Director, Division of Gastroenterology/ Hepatology</investigator_title>
  </responsible_party>
  <keyword>gastric intestinal metaplasia</keyword>
  <keyword>gastric neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

